The correct interpretation of a short cosyntropin test hinges on a few precise cortisol numbers. To diagnose adrenal insufficiency, clinicians rely on a peak serum cortisol below 18 µg/dL (500 nmol/L) 30 or 60 minutes after synthetic ACTH injection, or an incremental rise (delta) of less than 7–10 µg/dL (190–275 nmol/L) from baseline. A morning baseline below 5 µg/dL (138 nmol/L) strongly suggests deficiency, while any value above 18–20 µg/dL (500–550 nmol/L) reliably excludes it without further stimulation. These decision limits must be supported with high analytical accuracy by any cortisol immunoassay used in this dynamic endocrine test.
The true challenge lies not in memorizing the numbers, but in ensuring the immunoassay can precisely and accurately measure cortisol across three critical concentration windows: the low baseline (<5 µg/dL), the rule-out zone (>18–20 µg/dL), and the subtle delta change of 7–10 µg/dL. Assay performance at these exact thresholds determines whether a patient is correctly diagnosed or mistakenly labeled as adrenal-deficient.
Key Thresholds for Baseline and Stimulated Cortisol
The short cosyntropin test evaluates the adrenal cortex’s reserve capacity. It produces three distinct decision points that any cortisol immunoassay must faithfully report.
Morning Baseline Levels: The Rule-Out and Rule-In Zones
A pre-injection morning cortisol samples the adrenal glands at their natural peak.
This single value can often circumvent the need for a full stimulation test.
A level below 5 µg/dL (138 nmol/L) provides presumptive evidence of glucocorticoid deficiency.
It flags a high probability of adrenal insufficiency and warrants immediate further investigation.
Conversely, a baseline cortisol exceeding 18–20 µg/dL (>500–550 nmol/L) effectively rules out deficiency.
In such cases, dynamic testing is usually unnecessary, because the adrenal axis is demonstrably capable of mounting a robust output.
These extremes define the high-confidence “rule-in” and “rule-out” zones.
The interpretive grey area between 5 and 18–20 µg/dL is precisely where the short cosyntropin test adds most value.
Peak Post-Stimulation Thresholds: Defining Adrenal Insufficiency
After administering 250 µg of synthetic ACTH, blood is drawn at 30 and 60 minutes.
The highest cortisol value measured at either time point is the peak response.
A peak below 18 µg/dL (500 nmol/L) is the primary diagnostic cut-off for primary adrenocortical insufficiency.
This threshold applies regardless of age, gender, or the specific immunoassay platform, though assay-specific harmonization is vital for consistent classification.
A peak ≥18–20 µg/dL (500–550 nmol/L) indicates a normal adrenal response.
The slight variation (18 vs. 20 µg/dL) reflects differences in guidelines and assay designs, but most modern protocols consider 18 µg/dL the single actionable limit.
The Delta (Incremental Rise) Criterion
Some laboratories also evaluate the delta cortisol—the absolute increase from baseline to peak.
This metric ensures that even a low-normal baseline that blunts the rise does not escape detection.
A delta less than 7–10 µg/dL (190–275 nmol/L) confirms glucocorticoid deficiency.
If the rise is ≥7–10 µg/dL, adrenal function is typically considered intact, even if the absolute peak falls slightly short of 18 µg/dL.
Using both peak and delta criteria increases diagnostic sensitivity.
It guards against false-negative results in patients with a high initial cortisol who still fail to respond adequately to ACTH.
Why Immunoassay Performance Matters at These Limits
The thresholds are not merely clinical numbers—they are direct test specifications for assay developers and laboratory directors.
An immunoassay that cannot reliably measure cortisol near 5 µg/dL or differentiate between 17 and 18 µg/dL will produce misclassifications.
Precision at Low Concentrations (<5 µg/dL)
Analytical precision around 5 µg/dL is non-negotiable.
Even a small positive bias can push a truly-deficient patient’s value into the indeterminate zone, delaying the diagnosis.
The assay’s lower limit of quantification (LLoQ) must sit well below 5 µg/dL.
Manufacturers should demonstrate a coefficient of variation (CV) <20% at this level, ideally much lower, to give clinicians confidence in the “rule-in” signal.
Linearity Across the Critical Range
Cortisol must be measured accurately from <5 µg/dL to >20 µg/dL.
Assays must show excellent linearity throughout this span, with minimal sample dilution effects and no hooking at the high end.
Any non-linearity near 18 µg/dL is particularly dangerous.
A slight under-recovery here can falsely categorize a normal peak as deficient, leading to unnecessary lifelong hormone replacement.
Cross-Reactivity with Synthetic Steroids
Synthetic ACTH (cosyntropin) itself does not interfere, but patients may take other steroids.
Common cortisol immunoassays can exhibit cross-reactivity with prednisolone, prednisone, or dexamethasone, artificially inflating or deflating results.
A high-quality assay for dynamic testing must have negligible cross-reactivity (<1%) with synthetic glucocorticoids.
This ensures that pharmacological steroids do not mask or mimic a true adrenal insufficiency during the test.
Understanding the Trade-offs
Even with perfect assay performance, the interpretation of short cosyntropin test results involves inherent clinical and analytical trade-offs.
Laboratories must balance sensitivity against specificity, and clinicians must account for assay variability.
The Impact of Assay Method Differences
Immunoassay platforms vary in their calibration, antibody specificity, and reference ranges.
A value of 17.5 µg/dL on one system might read 18.5 µg/dL on another, straddling the decision threshold.
This inter-assay variability can shift a patient from “normal” to “deficient.”
Guideline thresholds of 18 µg/dL were historically established using polyclonal radioimmunoassays, but many modern automated immunoassays use different standardization (e.g., ID‑GC‑MS alignment), potentially demanding an assay-specific cut-off.
Laboratories must verify the appropriate threshold for their specific immunoassay through local validation.
Handling the Indeterminate Zone
Baseline values between 5 and 18–20 µg/dL are indeterminate, but the dynamic test itself can produce borderline peak values.
A peak cortisol of 16–18 µg/dL is a diagnostic grey area, particularly in critically ill patients or those with low albumin, where measured total cortisol may not reflect free, biologically active hormone.
Relying on the delta criterion adds another layer of complexity.
A patient with a baseline of 12 µg/dL and a peak of 18 µg/dL has a delta of only 6 µg/dL, which meets the delta deficiency threshold even though the peak is “normal.”
Such discrepancies force a tailored clinical judgement, highlighting why no single number is absolute.
Making Your Assay Fit for Purpose
The right assay and decision thresholds are not one-size-fits-all—they depend on your specific clinical or development goal.
Choose a strategy that aligns with your tolerance for diagnostic uncertainty.
- If your primary focus is ruling out adrenal insufficiency with confidence: Ensure your immunoassay achieves high precision and accuracy at >18 µg/dL, and validate a strict rule-out cut-off of 18–20 µg/dL with local reference data.
- If your primary focus is screening for deficiency with a standalone morning baseline: Prioritize an LLoQ well below 5 µg/dL and minimize bias at low concentrations to avoid missing early-stage Addison disease or iatrogenic suppression.
- If your primary focus is enhancing sensitivity in dynamic testing: Always report both the peak cortisol and the delta (7–10 µg/dL threshold), and select an immunoassay with proven linearity and low cross-reactivity to prevent misleading steroid interference.
- If your primary focus is standardizing results across a health system: Harmonize cortisol measurements by calibrating all immunoassay instruments to a common reference method (e.g., ID‑GC‑MS), and apply the same validated cut-offs universally, with clear interpretive comments for borderline values.
A reliable cortisol immunoassay converts the simple three-number logic of the short cosyntropin test into a robust clinical decision—because at 18 µg/dL, the difference between “healthy” and “deficient” hangs in the balance of analytical precision.
Summary Table:
| Diagnostic Parameter | Clinical Threshold | Diagnostic Interpretation | Immunoassay Performance Requirement |
|---|---|---|---|
| Morning Baseline | < 5 µg/dL (138 nmol/L) | Presumptive Adrenal Insufficiency (Rule-In) | Low LLoQ & high precision at low concentrations |
| Morning Baseline | > 18–20 µg/dL (500–550 nmol/L) | Excludes Deficiency (Rule-Out, no test needed) | Linear range spanning up to >20 µg/dL |
| Peak Post-ACTH (30/60 min) | < 18 µg/dL (500 nmol/L) | Confirms Adrenal Insufficiency | High analytical accuracy near 18 µg/dL threshold |
| Delta Rise (Peak − Baseline) | < 7–10 µg/dL (190–275 nmol/L) | Indicates Impaired Adrenal Reserve | Minimal inter-assay bias & low cross-reactivity |
Optimize Your Steroid Immunoassays with CamelBio
Delivering clinical precision at critical decision cut-offs like 5 µg/dL and 18 µg/dL requires high-affinity antibodies and uncompromised assay design. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you are developing next-generation endocrine assays or seeking reliable raw materials for standardized testing, our technical experts are here to help.
Contact CamelBio Today to elevate your IVD assay development!